Related Experiment Video
Updated: Jan 14, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Comprehensive Review on How Repurposed Drugs Modulate Antitumor Immunity: Harnessing Damage-Associated Molecular
Rahaman Shaik1,2, Maheshwari Sappidi2, Deepika Vemula2
1Department of Pharmacology, School of Pharmaceutical Education & Research, Jamia Hamdard University, New Delhi, India.
None:
Recent research has significantly altered the understanding of the immunogenic profile of certain processes of cancer cell death, leading to the recognition of a new subclass of apoptosis called "immunogenic apoptosis." This form of cell death, induced by specific chemotherapeutic agents, has been shown to elicit a "chemotherapy vaccine effect" in vivo, effectively stimulating an antitumor immune response. At the molecular level, "a collection of molecules" known as "damage-associated molecular patterns (DAMPs)" have been identified as key contributors to the immunogenicity of various cell death pathways. Intracellular molecules, such as heat-shock proteins, high-mobility group box 1 protein, and calreticulin, act as DAMPs when exposed or secreted in response to specific certain stressors, stimuli, and modes of cell death. These discoveries have fueled ongoing research focused on the identification of novel DAMPs, uncovering new mechanisms of their exposure or secretion and developing therapeutic agents capable of inducing immunogenic cell death (ICD). In addition, there is growing interest in addressing the current challenges and limitations within this emerging paradigm. The authors believe that this integrated strategy-combining DAMPs, ICD, and anticancer therapies-may hold the key to significantly reducing cancer-related mortality in the near future.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...